Use of Ebola Vaccine: Expansion of Recommendations of the Advisory Committee on Immunization Practices To Include Two Additional Populations - United States, 2021

On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Im...

Full description

Saved in:
Bibliographic Details
Published in:MMWR. Morbidity and mortality weekly report 2022-02, Vol.71 (8), p.290-292
Main Authors: Malenfant, Jason H, Joyce, Allison, Choi, Mary J, Cossaboom, Caitlin M, Whitesell, Amy N, Harcourt, Brian H, Atmar, Robert L, Villanueva, Julie M, Bell, Beth P, Hahn, Christine, Loehr, Jamie, Davey, Richard T, Sprecher, Armand, Kraft, Colleen S, Shoemaker, Trevor, Montgomery, Joel M, Helfand, Rita, Damon, Inger K, Frey, Sharon E, Chen, Wilbur H
Format: Article
Language:English
Subjects:
Adult
Advisory Committees
Centers for Disease Control and Prevention, U.S
Drug approval
Ebola Vaccines - administration & dosage
Ebola virus
Ebola virus infections
Ebolavirus
Exposure
Fever
Health aspects
Health Personnel
Health Planning Guidelines
Health risks
Hemorrhagic Fever, Ebola - prevention & control
Humans
Illnesses
Immunization
Infection
Infections
Infectious diseases
International economic relations
Laboratory Personnel
Medical laboratories
Medical personnel
Occupational exposure
Occupational Exposure - prevention & control
Occupational health
Pathogens
Pharmaceutical industry
Polls & surveys
Populations
Prevention
Public health
Risk
United States - epidemiology
Vaccination
Vaccines
Viral diseases
Virus diseases
Viruses
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:On December 19, 2019, the Food and Drug Administration (FDA) approved rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO, Merck) for the prevention of Ebola virus disease (EVD) caused by infection with Ebola virus, species Zaire ebolavirus, in adults aged ≥18 years. In February 2020, the Advisory Committee on Immunization Practices (ACIP) recommended preexposure vaccination with ERVEBO for adults aged ≥18 years in the United States who are at highest risk for potential occupational exposure to Ebola virus because they are responding to an outbreak of EVD, work as health care personnel at federally designated Ebola treatment centers in the United States, or work as laboratorians or other staff members at biosafety level 4 facilities in the United States (1).
ISSN:0149-2195
1545-861X
DOI:10.15585/mmwr.mm7108a2